@article{oai:nagasaki-u.repo.nii.ac.jp:00002104,
 author = {Fukuda, Minoru and Suetsugu, Takayuki and Shimada, Midori and Kitazaki, Takeshi and Hashiguchi, Kohji and Kishimoto, Junji and Harada, Taishi and Seto, Takashi and Ebi, Noriyuki and Takayama, Koichi and Sugio, Kenji and Semba, Hiroshi and Nakanishi, Yoichi and Ichinose, Yukito},
 issue = {4},
 journal = {Thoracic Cancer},
 month = {Jul},
 note = {Background: Uridine 5′-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. Methods: Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ? 80, combination ? 50, radiation with single ? 50, or radiation with combination ? 40 mg/m2; age ? 20; and Eastern Cooperative Oncology Group performance score (PS) 0?2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible. Results: UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/?, *6/?, ?/? observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively). Conclusion: Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients., Thoracic Cancer, 7(4), pp.467-472; 2016},
 pages = {467--472},
 title = {Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)},
 volume = {7},
 year = {2016}
}